Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice

por Goodlett, Charles R., Stringer, Megan, LaCombe, Jonathan, Patel, Roshni, Wallace, Joseph M., Roper, Randall J.
Publicado 2020

Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models

por Jamal, Raza, LaCombe, Jonathan, Patel, Roshni, Blackwell, Matthew, Thomas, Jared R., Sloan, Kourtney, Wallace, Joseph M., Roper, Randall J.
Publicado 2022

Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with Down syndrome

por Thomas, Jared R., LaCombe, Jonathan, Long, Rachel, Lana-Elola, Eva, Watson-Scales, Sheona, Wallace, Joseph M., Fisher, Elizabeth M.C., Tybulewicz, Victor L.J., Roper, Randall J.
Publicado 2020